Phaseline

Companies › Natureceuticals Sdn Bhd

Natureceuticals Sdn Bhd: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nuvastatic 300–Phase 3Fatigue Related to Cancer Treatment; FatigueNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07669467Nuvastatic 300Phase 3Fatigue Related to Cancer TreatmentOncologyOct 2026
NCT07669454Nuvastatic 300Phase 3Fatigue Related to Cancer TreatmentOncologyNov 2026
NCT07669519Nuvastatic 300Phase 3FatigueOncologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.